Aripiprazole-induced neuroleptic malignant syndrome

Prashant Tibrewal, Tarun Bastiampillai, Cutie Kannampuzha, Jennifer Hancox, Rohanjeet Dhillon

Research output: Contribution to journalLetter

4 Citations (Scopus)

Abstract

Antipsychotics can be effective in augmenting mood-stabilisers for bipolar affective disorder (BPAD) but pose the risk of neuroleptic malignant syndrome (NMS). NMS is characterised by the classic tetrad of altered mental status, extrapyramidal symptoms (EPS), pyrexia and autonomic instability (Belvederi Murri et al., 2015) – typically developing in that order (Velamoor et al., 1994). The incidence of NMS in those treated with neuroleptics is low and has declined to 0.01–0.02% due to newer atypical antipsychotic medication, improved prescribing practice, and earlier detection and management of NMS (Berman, 2011). We describe a case of aripiprazole-induced NMS in a patient with a prior history of NMS.
Original languageEnglish
Pages (from-to)5-6
Number of pages2
JournalAsian Journal of Psychiatry
Volume27
Early online date9 Feb 2017
DOIs
Publication statusPublished - Jun 2017
Externally publishedYes

Keywords

  • Aripiprazole
  • Neuroleptic Malignant Syndrome
  • Antipsychotics

Fingerprint Dive into the research topics of 'Aripiprazole-induced neuroleptic malignant syndrome'. Together they form a unique fingerprint.

  • Cite this